-
Anesthesiology
-
Cardiology and Cardiovascular Surgery
-
Critical Care and ICU
-
Dentistry
-
Dermatology
-
Endocrinology
-
ENT, Head and Neck Surgery
-
Gastroenterology
-
General and Laparoscopic Surgery
-
General Medicine
-
Gynecology and Obstetrics
-
Immunology and Allergy
-
Internal Medicine
-
Neuroscience
-
Neurosurgery
-
Nuclear Medicine
-
Nutrition and Dietetics
-
Oncology
-
Ophthalmology
-
Orthopedics and Sports Medicine
-
Pathology
-
Pediatric & Neonatology
-
Pediatric Surgery
-
Physiotherapy
-
Pulmonology
-
Radiology
-
Urology
-
Vascular and Endovascular Surgery
At Burjeel Specialty Hospital, Sharjah, we are proud to offer the city's first comprehensive Nuclear Medicine and PET-CT Centre, delivering advanced molecular imaging. Integrated with the Burjeel Cancer Institute (BCI), our department combines cutting-edge technology with multidisciplinary expertise to provide accurate diagnosis, personalized treatment planning, and comprehensive cancer care.
Advanced PET-CT Technology
Our centre is equipped with the GE Discovery IQ PET-CT, offering:
- High-resolution molecular imaging
- Faster scan times for greater patient comfort
- Lower radiation exposure without compromising image quality
- Accurate quantitative imaging for treatment response assessment
- Enhanced lesion detection and diagnostic confidence
Who Can Benefit From Our PET-CT Imaging
Our PET-CT imaging supports the diagnosis, staging, and monitoring of a wide range of conditions, including:
- Lung cancer
- Breast cancer
- Prostate cancer
- Liver cancer
- Thyroid cancer
- Hodgkin’s and non-Hodgkin’s lymphoma
- Neuroendocrine tumours
- Bone metastases
- Other solid tumours
Our advanced imaging helps physicians make informed treatment decisions and monitor therapy effectiveness throughout the patient’s journey.
Our Diagnostic Services
As part of our Nuclear Medicine department, we offer a comprehensive range of PET-CT radiotracers tailored to specific clinical indications:
| Radiotracer | Primary Clinical Use |
| F18 FDG PET-CT | General oncology staging — most solid tumours and lymphomas |
| 68Ga DOTA-peptide PET-CT (DOTATATE/DOTANOC/DOTATOC) | Neuroendocrine tumours |
| Radiotracer | Primary Clinical Use |
| F18 FDG PET-CT | General oncology staging — most solid tumours and lymphomas |
| 68Ga DOTA-peptide PET-CT (DOTATATE/DOTANOC/DOTATOC) | Neuroendocrine tumours |
| 68Ga / F18 PSMA PET-CT | Prostate cancer detection and staging |
| F18 DOPA PET-CT | Neuroendocrine tumours and selected neurological indications |
| F18 Choline PET-CT | Prostate cancer and parathyroid imaging |
| F18 FES PET-CT | Estrogen receptor-positive breast cancer |
| F18 FET PET-CT | Brain tumour imaging |
| 68Ga FAPI PET-CT | Fibroblast-targeted imaging across multiple tumour types |
| F18 Florbetaben PET-CT | Amyloid imaging for evaluation of Alzheimer’s disease and cognitive impairment (neurology indication) |
These molecular imaging studies assist in:
- Early cancer detection
- Disease staging
- Treatment planning
- Monitoring treatment response
- Detecting recurrence
- Precision diagnosis of complex diseases
Nuclear Medicine Therapy Guidance
This collaborative approach with Burjeel Cancer Institute enables:
- Comprehensive cancer evaluation
- Multidisciplinary tumour board discussions
- Personalized treatment plans
- Coordinated specialist consultations
- Continuous monitoring throughout treatment
From diagnosis to guided access to advanced therapy, our teams work together to provide seamless, patient-centred care. In collaboration with the Burjeel Cancer Institute in Abu Dhabi, our team coordinates clinical guidance, specialist consultation, and referral pathways for the following therapies:
Radioactive Iodine (I-131) Therapy
Targeted treatment for thyroid cancer and selected thyroid disorders.
Peptide Receptor Radionuclide Therapy (PRRT)
A highly targeted treatment for neuroendocrine tumours.
Lutetium-177 PSMA Therapy
An advanced precision therapy for patients with advanced prostate cancer
Selective Internal Radiation Therapy (SIRT/TARE)
Targeted liver cancer treatment using radioactive microspheres delivered directly to liver tumours
